Role of allogeneic natural killer T cells in the treatment of a patient with gefitinib-sensitive lung adenocarcinoma

Author:

Yu Wanjun12ORCID,Yuan Xiao3,Ye Fei3,Mao Chaoming4,Li Jian5ORCID,Zhang Minghui6,Chen Deyu3,Xia Sheng1ORCID

Affiliation:

1. Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu Province, 212013, China

2. Department of Clinical Laboratory, QingPu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, 201700, China

3. Department of Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, 212001, China

4. Department of Nuclear Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, 212001, China

5. Department of Pneumology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, 212001, China

6. School of Medicine, Tsinghua University, Beijing, 100084, China

Abstract

Gefitinib has shown good efficacy in patients with EGFR mutation-positive non-small-cell lung cancer, but acquired resistance is inevitable. Here we report a patient with an advanced lung adenocarcinoma with the EGFR mutation who achieved surgical opportunity and long-term survival following treatment with chemotherapy and bevacizumab, followed by sequential gefitinib combined with allogeneic haploidentical CD8+ CD56+ natural killer T cells. Our case provides a potential effective strategy for delaying acquired gefitinib resistance and extending progression-free survival among patients with non-small-cell lung cancer who harbor common EGFR mutations.

Funder

National Natural Science Foundation of China

Jiangsu Provincial Key Research and Development Program

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3